MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis

• Published in: Haematologica (Roma) Vol. 105; no. 2; pp. 424 - 434
• Main Authors: Vermaat, Joost S, Somers, Sebastiaan F, de Wreede, Liesbeth C, Kraan, Willem, de Groen, Ruben A L, Schrader, Anne M R, Kerver, Emile D, Scheepstra, Cornelis G, Berenschot, Henriëtte, Deenik, Wendy, Wegman, Jurgen, Broers, Rianne, de Boer, Jan-Paul D, Nijland, Marcel, van Wezel, Tom, Veelken, Hendrik, Spaargaren, Marcel, Cleven, Arjen H, Kersten, Marie José, Pals, Steven T
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01.02.2020
• Subjects: Epstein-Barr Virus Infections - genetics; Herpesvirus 4, Human; Humans; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - genetics; Mutation; Myeloid Differentiation Factor 88 - genetics; Prognosis
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2018.214122

The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic rearrangements of as drivers of lymphomagenesis. A subset of DLBCL, however, is characterized by activating mutations in We investigated whether mutations could improve the classification and prognostication of DLBCL. In 250 primary DLBCL, mutations were identified by allele-specific polymerase chain reaction or next-generation-sequencing, rearrangements were analyzed by fluorescence hybridization, and EBV was studied by EBV-encoded RNA hybridization. Associations of molecular features with clinicopathologic characteristics, outcome, and prognosis according to the International Prognostic Index (IPI) were investigated. and mutations were identified in 29.6% and 12.3%, , and rearrangements in 10.6%, 13.6%, and 20.3%, and EBV in 11.7% of DLBCL, respectively. Prominent mutual exclusivity between EBV positivity, rearrangements, and mutations established the value of molecular markers for the recognition of biologically distinct DLBCL subtypes. -mutated DLBCL had a significantly inferior 5-year overall survival than wild-type DLBCL (log-rank; =0.019). DLBCL without any of the studied aberrations had superior overall survival compared to cases carrying ≥1 aberrancy (log-rank; =0.010). mutations retained their adverse prognostic impact upon adjustment for other genetic and clinical variables by multivariable analysis and improved the prognostic performance of the IPI. This study demonstrates the clinical utility of defining -mutated DLBCL as a distinct molecular subtype with adverse prognosis. Our data call for sequence analysis of in routine diagnostics of DLBCL to optimize classification and prognostication, and to guide the development of improved treatment strategies.